On June 14, 2018, Mylan Pharmaceuticals Inc. received FDA approval to launch Buprenorphine and Naloxone tablets, bringing a potent generic alternative to the drug market offering mixed buprenorphine naloxone. This approval positions Mylan to increase its share of the pharmacy benefit segments, specifically addressing the demand for effective addiction treatment solutions with an alternative dosage form to its existing line of products.